SecBot SecBot
4258-K ·Filed Jul 22, 2026

RGEN

REPLIGEN CORP
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-311411
Actionable Insight ▲ Bullish

Monitor regulatory filings (HSR, SEC S-4) and BioLife shareholder vote for deal closure timeline. Repligen's full Q2 earnings on July 28 will provide further detail on organic growth trajectory and margin expansion. The acquisition positions Repligen in the high-growth cell therapy market, but integration risk and potential dilution from share issuance are key watchpoints.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$140.09
T+0 close · Jul 22, 2026 · via day close
Latest settled
+31.47%
T+60 · $184.17
Vs SPY
+28.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $140.09entry
  2. T+1 · 4mo ago −1.78%α −0.54% · $137.60
  3. T+5 · 4mo ago +0.81%α +3.22% · $141.23
  4. T+20 · 3mo ago +25.89%α +22.99% · $176.36
  5. T+60 · 5w ago +31.47%α +28.20% · $184.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal, expanding its cell therapy capabilities. The company also reported preliminary Q2 2026 revenue growth of ~12% (13% organic) and expects strong margin expansion. The transaction is expected to close in Q4 2026 and be accretive to adjusted EPS by at least $0.05 in year one.

Key Financial Metrics

Deal Value
$1.5B
Premium
24%
Deal Type
acquisition

Key Facts

  • Acquisition of BioLife Solutions for $11.25 cash + 0.1442 RGEN shares per BLFS share, total enterprise value ~$1.5B
  • Implied premium of 24% to 90-day VWAP
  • Expected to close in Q4 2026, subject to regulatory and BioLife shareholder approvals
  • Repligen expects at least $20M synergies in year one, $30M in year two
  • Accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two
  • Preliminary Q2 2026 revenue growth of ~12% reported, 13% organic vs Q2 2025
  • BioLife preliminary Q2 2026 revenue of $28.5M, up 21% YoY
  • Repligen expects strong year-over-year margin expansion in Q2 2026

Financial Impact

~$1.5B enterprise value acquisition; Repligen Q2 revenue growth ~12% reported; BioLife Q2 revenue $28.5M

revenueepsmarginsdilution

Risk Factors

  • Integration risk and potential disruption to existing operations
  • Failure to obtain regulatory or shareholder approvals
  • Dilution from issuance of ~7.2M RGEN shares (approx 12.8% of outstanding)
  • Synergy targets may not be achieved

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (RGEN), Batch item 10001193125-26-311411
Document: 0001193125-26-311411-index-headers.html0001193125-26-311402
Document: 0001193125-26-311411-index.html0001193125-26-311411
Document: 0001193125-26-311411.txt0001193125-26-311411
8-K Filing (RGEN), Batch item 50001193125-26-311402
8-K Data (Synthetic)0001193125-26-311411

US Market Status

Market Closed · Opens Wed (11h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026